Drugs / CV9104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02140138 | Jun 2014 → Apr 2016 | prostate carcinoma | CureVac | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01817738 Comparator | Aug 2012 → Aug 2016 | prostate cancer | CureVac | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CV9104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01817738 ↗ |
| Modality | Messenger RNA (mRNA) | “2 x 80 μg mRNA per injection” NCT02140138 ↗ |
| Route | Other | “CV9104 intradermal injection” NCT01817738 ↗ |